Previous 10 | Next 10 |
Edgewise Therapeutics has filed to raise $150 million in an IPO. The firm is developing treatments for various degenerative neuromuscular diseases. EWTX is operating in a notoriously difficult research area and hasn't provided any Phase 1 initial results, so I'll watch the IPO fro...
PTC Therapeutics ([[PTCT]] -1.1%) has announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy.The double-blind, placebo-controlled pivotal study involving 180 patients aged 2- 25 yea...
Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients - Sustained or improved motor function was observed with 24 months of treatment - - Patients and caregivers reported a ...
PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies - Desire to slow disease progression and tolerability issues were the primary reasons for switching from prednisone to EMFLAZA® (deflazacort) - - Delay...
PTC Therapeutics (PTCT) and the Spinal Muscular Atrophy ((SMA)) Foundation have entered into a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders with the goal of developing new treatments.SMA is a severe, in...
Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine -SMA Foundation and PTC Therapeutics to commit to an initial investment of up to $60 million in research to discover and d...
The European Medicines Agency's advisory group has recommended the approval of PTC Therapeutics' (PTCT) Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy ((SMA)) in patients 2 months and older.The CHMP review was completed under the accelerated assessment pathway.The re...
CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older - Evrysdi is the first and only at-home treatment for SMA patients - - Opinion based on efficacy results from the FIREFISH and SUNFI...
PTC Therapeutics, Inc (PTCT) Q4 2020 Earnings Conference Call February 25, 2021 16:30 PM ET Company Participants Kylie O'Keefe - Head of Investor Relations Stuart Peltz - Founder and Chief Executive Officer Emily Hill - Chief Financial Officer Eric Pauwels - Chief Business Officer Matthew Kle...
PTC Therapeutics (PTCT): Q4 GAAP EPS of -$1.08 misses by $0.15.Revenue of $118.86M (+23.2% Y/Y) beats by $5.04M.Reaffirms Full Year 2021 Guidance as Follows:PTC anticipates net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.PTC anticipates GA...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....